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Biodegradable implants were suggested as an ideal biomedical 
implant due to the elimination of a second surgery to remove the devices after 
the healing of the surrounding tissues. Magnesium (Mg) and its alloys have 
gained considerable attention as a promising biomaterial for biodegradable
implants due to the outstanding mechanical properties and biocompatibility, 
especially in dental, orthopedic and vascular stent applications. However, 
despite the significant advantages of Mg, the excessively high corrosion rate 
of Mg and its alloys is one of the major drawbacks for clinical use of Mg-
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based implants. Therefore, in order to not only decrease the degradation rate 
but also enhance the biological responses to improve the function of the 
implant, various functional surface treatments have been performed. 
In the first study, PEI-Silica hybrid coated biomimetic Mg was 
fabricated for dental and orthopedic application. By mimicking the structure 
and component of the bone, biodegradable Mg implant with high strength and 
pore interconnectivity and good osteoconductivity can be acquired. Bone has 
structure with combined dense and porous structure resulting in high 
strength/density ratio. Furthermore, it is composed with hydroxyapatite (HA) 
which has excellent osteoconductivity. By spark plasma sintering and space 
holder process Mg scaffold with combined dense/porous structure can be 
fabricated. Due to the bone-mimicking structure, Mg implant can have high 
strength and stiffness with high pore interconnectivity. Moreover, by 
controlling the ratio of dense structure, mechanical strength and stiffness can 
be controlled. By aqueous precipitation coating method HA can be coated on 
the Mg implant. This HA layer can enhance both corrosion resistance and 
biocompatibility with osteoblast cells. However, cracks form on HA coating
layer due to the brittle property of HA. These cracks could be critical in 
corrosion and biological behavior on porous Mg due to complex shape and 
large surface area. Consequently, PEI-Silica hybrid layers were dual coated on 
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the bone-mimetic Mg. Due to the high corrosion resistance of PEI and 
excellent bioactivity of silica, corrosion rate of bone-mimetic Mg decreased 
remarkably and both biocompatibility and bioactivity with bone tissue were 
enhanced. Thus, PEI-Silica hybrid coated biomimetic Mg implant could be a 
promising biodegradable scaffold for dental and orthopedic applications.
In the second study, selective PEI/PLGA dual layer was coated on 
Mg for the biodegradable drug eluting stent application. Corrosion rate of Mg 
stent is need to be slowed down to maintain the scaffolding ability until the 
revascularization has been finished. Moreover, anti-proliferative drug is 
needed to be released to prohibit restenosis. To achieve these needs, Mg stent 
was selectively coated with PEI/PLGA dual layer by spray coating process. 
PEI was fully coated on the surface of the Mg stent to decrease the fast 
corrosion rate and improve the biocompatibility with endothelial cells. 
Subsequently, sirolimus loaded PLGA was selectively coated on abluminal 
side of the Mg stent to control the release of the drug to the wall of the blood 
vessel. This selective drug release can prohibit the proliferation of smooth 
muscle cells and prohibit the anti-proliferative effect to endothelial cell on 
luminal side of the Mg stent. Thus, selective PEI/PLGA dual coating on Mg 
stent offers a promising approach for the development of biodegradable drug 
eluting vascular stent application.
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In conclusion, these researches were about improving the functions
of the Mg implant by enhancing the corrosion resistance and biocompatibility 
with stable surface coatings for various biomedical applications. The 
degradation tests and in-vitro cell tests showed the PEI-Silica hybrid coating
and selective PEI/PLGA dual coating had effectively enhanced corrosion 
protection and cellular responses of Mg implant offering excellent function 
for dental/orthopedic application and vascular stent application respectively. 
Keywords: Magnesium (Mg); Surface coating; Corrosion resistance;
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1.1. Potential of Mg for biodegradable implants
Biodegradable implants were suggested as an ideal biomedical 
implant due to the elimination of a second surgery to remove the devices after 
healing of the surrounding tissues [2]. For example, poly(glycolide) (PGA), 
poly(caprolactone) (PCL), poly(L-lactide) (PLA) and their copolymers were 
suggested as a polymer for biodegradable implant due to the non-toxic and 
biocompatible property [2]. However, due to the poor mechanical properties 
compared with those of the biodegradable metallic materials, these polymeric 
materials were limited to be applied actively for the medical applications [3-5]. 
Moreover, a local inflammation was found occasionally during the 
degradation process of the biodegradable polymer implants [2].
A magnesium (Mg) and its alloys were actively applied in an 
engineering field due to high strength to weight ratio, high thermal 
conductivity, and good machinability [6, 7]. Recently, magnesium and its 
alloys have gained considerable attention as a promising biodegradable 
implant due to its outstanding mechanical properties and biological 
performances. Moreover, in contrast with other metallic materials, Mg has 
comparable density (1.74-2.0 g/cm3) and elastic modulus (41-45 GPa) to those 
of human natural bone (1.8-2.1 g/cm3, 3-20 GPa) as shown in Table 1.1., thus 
minimizing stress-shielding effects [1, 5, 8]. In biological performance, it was 
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explained that during the degradation of Mg implant non-toxic by-products 
are formed and can be tolerated by the human body without any harmful 
effect [5, 9]. It is because degradation products are likely to be excreted 
readily through the kidney [1, 5, 8, 10]. Moreover, degradation products are 
also known to stimulate bone growth, accelerating bone regeneration by 
stimulating a hydroxyapatite (HA) formation which is one of the main 
component of the bone [8].
1.2. Limitation of Mg in physiological 
environment
Despite the excellent properties of Mg, the rapid corrosion rate of 
Mg and its alloys is one of the major drawbacks for clinical use of Mg-based 
implants [1, 5, 11, 12]. Mg forms a slightly soluble magnesium hydroxide 
(Mg(OH)2) in a water which is passivation layer of the Mg, inducing it to be 
degraded slowly. As shown in the redox potential pH-value diagram (Figure 
1.1.), the Mg(OH)2 can be degraded when the pH value is lower than 10 [13]. 
Therefore, in physiological conditions, the pH of the human body cannot 
exceed 10, making the Mg possible as the biodegradable material. 
Nonetheless, the Mg degradation rate would be faster in a 
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physiological condition which has high chloride (Cl-) concentration [12, 14]. 
The reason is that the passivation layer of Mg(OH)2 easily reacts with Cl
-, 
forming a highly soluble magnesium chloride (MgCl2) and hydrogen gas (H2). 
Considering the fact that a pitting corrosion occurs in the 30 mmol/L of Cl-
concentration, the degradation would be accelerated in the physiological 
environment with higher concentration of Cl- (150 mmol/L Cl-). These 
reactions are summarized and illustrated by a following chemical reaction 
formula and schematic diagram as shown in Figure 1.2. [4, 15].
Mg(s) + 2H
+










(aq) → MgCl2(aq) + 2OH
-
(aq)
The fast degradation of the Mg prohibits the bone regeneration and 
defect healing. Moreover, it was reported that the by-products formed during 
the rapid degradation caused serious problems. The accumulated hydrogen 
gas could delay healing and occur necrosis of near tissue by separating tissue 
and tissue’s layers [4]. Furthermore, the radical increase of pH also resulted in 
the chronic local inflammatory, alkaline poisoning effect [4].
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1.3. Surface coating to control the corrosion of Mg
1.3.1. Surface coating 
Surface coating is one of the excellent process as it shows better 
performance in decreasing the degradation rate of Mg and improving its 
bioactivity while maintaining the inherent mechanical properties of Mg 
implant. Ideal surface coating on Mg implant would slow down the corrosion 
to maintain the mechanical integrity of the metal implant during tissue healing
as shown in Figure 1.3. By slowing down the corrosion of Mg implant,
hydrogen evolution and increase of pH, which have been observed as 
potential dangerous corrosion by-product, would be restrained. The slow wear 
away or degradation of coatings allow the control of degradation rate of Mg 
implant [16]. A various coating techniques and coating materials depending 
on the applications are another attractiveness of surface coating. Various 
coating techniques such as the chemical conversion, alkali heat treatment, 
anodic and micro arc oxidation, electrodeposition, and sol-gel methods were 
researched and applied in various applications. Furthermore, for the coating 
materials of biomedical application many studies focus on bio-ceramics, in 
particular calcium phosphate group, and bio-polymers, due to their good 
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corrosion resistance and biocompatibility [16-18].
1.3.2. Bio-ceramic coating
Bio-ceramics, in particular calcium phosphate, have many attractive 
properties for coating material in biomedical application since they have 
excellent corrosion resistance and biocompatibility [19-22]. They have a 
similar chemical composition and architecture to those of the mineral 
component of bones, resulting in less immune response and excellent 
biocompatibility with osseous tissues. Due to these properties calcium 
phosphate based bio-ceramics are often used in bone related biomedical 
application, integrating into living tissues and actively remodeling healthy 
bones [23]. In consequence, bio-ceramic coating particularly calcium 
phosphate coatings are of special interest for surface modification of Mg in
dental and orthopedic applications in terms of excellent corrosion protection 
and bioactivity.
Various calcium phosphate based bio-ceramic coatings have been 
applied in various techniques showing great potential for biomedical 
applications. Among various methods simple chemical immersion techniques 
have been researched to coating calcium phosphate on Mg implant. Zhang et 
al. have introduced the hydroxyapatite (HA) coatings which is a component of 
the bone by immersing pure Mg into three times concentrated simulated body 
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fluid (SBF) for 24 h at 42 °C [22]. By the HA coating corrosion rate of Mg 
has been decreased and as the thickness of HA coatings layer increased by 
longer immersion time in SBF the corrosion slowed down further. Yang et al. 
have also introduced HA coating technique by immersing Mg in 
supersaturated calcification solution containing Ca(NO)3, NaH2PO4, and 
NaHCO3 at 37 °C for 48 h, followed by 2 h heat treatment at 300 °C [16]. 
Corrosion of Mg has been remarkably restrained and Ca/P contents in HA 
coating decreased showing the degradation of the HA coating layer.
Micro-arc oxidation (MAO) is one of the effective method to coat 
with uniform coating layer and high surface area. MAO is performed in 
electrolyte with calcium and phosphorus ions with a high voltage spark 
treatment occurring electrochemical oxidation to coat Mg. Srinivasan et al. 
have performed MAO using the Ca(OH)2 and Na3PO4 electrolytes with 
different mass ratios to coat on AM50 alloys [24]. Coating layers on AM50 
were constituted with MgO and Mg3(PO4)2 and the phase composition was
influenced by the phosphate ion concentration and conductivity of the 
electrolyte. 
Furthermore, calcium phosphate with different compositions have 
been researched for the better performances in biological response. Ravazi et 
al have introduced fluoridated HA (FHA) coating on micro-arc oxidized AZ91
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alloy by electrophoretic deposition (EPD) [25]. By performing in-vivo tests, a 
significant enhancement in the corrosion resistance and biocompatibility of 
FHA/MAO coated Mg compared to the uncoated one were shown. Moreover, 
new bone was formed around the coated implant with less inflammation, 
showing the FHA/MAO coated implant would be a suitable candidate for 
future clinical biomedical applications. Furthermore, Wang et al. suggested a 
Ca deficient HA coating on Mg by pulse electrodeposition process using 
positive and reverse currents [26]. The coating layer slowed down the 
corrosion of Mg and improved bone regeneration [27]. Moreover, this 
technique was reported to significantly improve the bonding strength between 
coating and substrate to (41.8 ± 2.7) MPa [26].
1.3.3. Bio-polymer coating
Bio-polymers are another promising candidate for the coating material 
on Mg implant due to the various chemical and physical functions they can 
offer. Bio-polymers already have been used in various biomedical applications 
such as membranes, drug carrier, contact lenses, catheters, breast implants, 
bone screws, etc [28]. In consequences, researchers have focused on polymer 
coatings due to the performances of bio-polymers, such as biocompatibility, 
elasticity and biodegradability, etc. Moreover, the degradable polymer 
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coatings, such as poly(caprolactone) (PCL), poly(L-lactic acid) (PLLA), and 
poly(DL-lactic-co-glycolide) (PLGA), have been getting attention due to the 
ideal function in biodegradable Mg coating material which protect the Mg 
implant in the early stage and gradually degrade [17]. Thus various polymer 
based coatings have been applied in different methods to improve the 
corrosion resistance of Mg substrate.
Spin coating technique is one of the simplest and fastest method to coat 
polymer in uniform thickness. Xu et al. have prepared the uniform and non-
porous PCL and PLLA coatings on Mg substrate using spin coating technique 
[29, 30]. The PLLA coating provided better protection and bonding to Mg 
substrate than the PCL coating. Furthermore, polymer coating with lower 
molecular weight had lower bonding strength with Mg substrate results in 
faster corrosion than polymer coatings with the high molecular weight.
Alternatively, dip coating is one of the effective method to apply 
polymer coatings on complex shaped implants. Diez et al. have prepared a 
PLLA dual coating on HA coated WE43 alloy by dip coating method with a 
coating thickness of 3 mm for both HA and PLLA [31]. The additional PLLA 
coating layer provided good protection to the HA coated WE43 alloy from 
corrosion regardless of deformation. Gu et al. have applied the chitosan dip 
coating on Mg-Ca alloy and found that the performances of chitosan coating
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depends on the molecular weight of the chitosan and the number of coating 
cycles [32].
Additionally, Wong et al. sprayed the PCL solution on the AZ91 alloy 
layer by layer and the porous polymer membrane was obtained [33]. The 
porosity of the PCL membrane was related to the PCL concentrations and thus 
influenced the corrosion behavior. The in-vitro and in-vivo corrosion tests 
indicated that the AZ91D with low porosity coatings exhibited slower 
corrosion rate than that with high porosity coatings.
Likewise, several materials and techniques were applied to Mg and Mg 
alloys to improve corrosion resistance and biocompatibility. Among various 
biomedical applications magnesium is widely studied on dental, orthopedic 
and vascular stent applications, recently. With different applications 
biodegradable magnesium implant not only need to control the corrosion rate 
but also enhance the functions according to the applications. In this study, 
magnesium structure has been controlled, and various bio-ceramic and bio-
polymer were coated in different techniques according to the dental, 









Natural bone 1.8-2.1 130-180 3-20
Magnesium 1.74-2.0 65-100 41-45
Titanium 4.4-4.5 758-1117 110-117
Co-Cr 8.3-9.2 450-1000 230
Stainless steel 7.9-8.1 170-310 189-205
Table 1.1. Summary of the mechanical properties of various metal implant 
materials compared to natural human bone (Redrawn from ref [1])
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Figure 1.1. redox potential pH-value diagram for the Mg in water at 25 °C
(Redrawn from ref [34])
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Figure 1.2. The schematic illustration of corrosion reactions of Mg in human 
body fluid. (a) the galvanic reaction between substrate and H2O and (b) the 
decomposition of Mg(OH)2 by Cl
- (Redrawn from ref [15])
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Metals have proven to be optimal materials for dental and orthopedic 
implants owing to their excellent strength and ductility, outperforming 
polymers and ceramics, especially in load bearing applications [35-38]. 
Titanium and its alloys, stainless steel, and cobalt–chromium alloys are 
widely used for bone fracture implants [39-42]. However, secondary surgery 
may be required after implantation of current metallic materials because of 
removal of implant after healing and adverse effects such as implant 
intolerance or loosening during prolonged healing, increasing health care 
costs, and patient discomfort [43-45]. As an alternative, biodegradable 
materials exhibiting sufficient mechanical stability and good biocompatibility 
have recently prompted much research interest. 
Magnesium (Mg) and its alloys display good biocompatibility and 
mechanical properties closely approximating those of bone tissues, making 
them potential candidates for biomedical applications [1, 46-48]. Unlike their 
conventional metallic equivalents, magnesium implants do not require 
additional surgical removal owing to their biodegradability and 
bioresorbability [49, 50]. Moreover, many studies have suggested that porous 
scaffolds, in which pores promote bone ingrowth for firmer scaffold fixation 
and nutrient transport for better wound healing, are suitable for dental and 
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orthopedic applications [41, 51-54]. Therefore, magnesium scaffolds with a 
porous structure are potentially promising materials for medical implant 
applications. 
However, one serious limitation in the use of porous Mg in medical 
implants is its excessively high corrosion rate. Not only does this fast bio-
corrosion behavior deteriorate the mechanical strength of Mg implants, but it 
also leads to hydrogen gas evolution, which hinders cell attachment [1, 8, 55-
57]. To inhibit corrosion of porous Mg, post-treatment is required, which may 
include surface treatment, alloying [1, 8, 55-57], or grain refinement [58]. 
Several studies have evaluated the effects of various Mg surface treatment 
methods, such as aerosol deposition, micro arc oxidation, fluoride treatment, 
and polymer coating [46, 50, 55, 59, 60], on the basis of degradation rates 
associated with different corrosion levels. Among these surface treatment 
methods, the hydroxyapatite (HA) coating through aqueous precipitation 
method was beneficial to coat complex shape of porous Mg with good 
corrosion resistance and biocompatibility with osteoblast cells [55-57]. 
In the previous research, HA coated porous Mg with different 
porosity (50-70%) has been fabricated [61]. However, the use of HA coated 
porous magnesium as a bone substitute under physiological conditions 
remains problematic. Porous magnesium structures in previous studies 
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demonstrated low strength and relatively fast corrosion rate in the human 
body [61-64]. Their applicability to implants require that their degradation 
rate not exceed the healing rate of the damaged tissue [65]. However, due to 
the inherent brittle performance of HA, cracks may form easily on HA coating 
layer during the deformation of the implant. Consequently, physiological fluid 
may penetrate through the cracks leading to the contact of the fluid with the 
Mg implant [66, 67]. Therefore, to successfully ensure the performance of 
load bearing Mg implants, a strategically designed porous magnesium 
scaffold with functional coating that simultaneously retains its excellent 
mechanical strength and corrodes at a controlled rate is necessary. 
First, the mechanical properties of porous Mg scaffolds could be
enhanced by mimicking the bone structure. Bone has combined dense and 
porous structure which may allow to have high strength and pore 
interconnectivity. By dense/porous combined structure of Mg scaffold as 
shown in Figure 2.1., Mg implant can have high strength while maintaining 
the advantages of porous structure. Therefore, in this study, we fabricated Mg 
mimicking the bone structure by spark plasma sintering process and space 
holder method. 
Furthermore, the degradation rate of the biomimetic HA coated 
porous Mg scaffold can be decreased by dual coating the scaffold with 
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polymer to cover the cracks on HA coating layer. Poly(ether imide) (PEI) 
polymers can be a good candidate for dual coating material due to excellent 
adhesion strength to Mg, induced by its polar aromatic imide rings, in 
addition to its good flexibility and biocompatibility [46, 68-70]. Nevertheless, 
the concerns about low bioactivity of the PEI coating have yet to be resolved. 
PEI is less osteoconductive due to the low bioactivity compared to Mg 
implants coated with bio-ceramics such as HA. Thus, in this study, we 
proposed PEI-Silica hybrid materials as a dual coating layer on HA coated 
porous Mg, which allows the tunable corrosion behavior and enhanced 
biological behavior of the hybrid coated Mg by varying the amount of silica. 
The incorporation of silica into PEI may increase the corrosion rate of Mg 
through the reduced barrier properties or decreased hydrophobicity of the PEI 
coating [71, 72]. Moreover, excellent bioactivity of silica xerogels creates 
good chemical bonding with the surrounding bone tissues [71, 72].
Herein, biomimetic porous Mg, which was generated by subjecting 
Mg/NaCl composites to spark plasma sintering (SPS) and dissolving NaCl 
granules, was coated with a HA layer by aqueous precipitation coating 
process. Furthermore, PEI-Silica hybrid layer was dual coated on HA layer 
for the improvement of corrosion resistance and bioactivity. Structure and 
morphology of biomimetic HA coated porous Mg were examined by scanning 
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electron microscopy (SEM) and micro tomography (μ-CT). In addition, X-ray 
diffraction (XRD) characterization, and mechanical tests were conducted. 
Furthermore, the morphology, chemical composition, and hydrophilicity of 
HA/PEI-Silica hybrid coating layers were evaluated in terms of silica contents. 
In particular, the corrosion behavior of porous Mg coated with HA/PEI-Silica 
hybrids was carefully assessed under physiological conditions, and compared 
to HA coated porous Mg. The improved biological performance of hybrid 




2.2.1. Fabrication of porous Mg
Mg powder (−100+200 mesh, Alfa Aesar, USA) and NaCl powder (+80 
mesh, Sigma Aldrich, USA) were mixed with a small amount of ethanol as a 
binder. To fabricate porous Mg with different levels of porosity, the volume 
fraction of NaCl powder was varied (50%, 60% and 70%). The mixed 
powders were put inside a carbon die with 12 mm inner diameter and pressed 
with a load of 20 MPa inside an SPS (Well Tech, Korea) chamber. The 
sintering temperature was 585 °C. A holding time of 2 h and heating rate of 
100 °C/min were employed during sintering. After densification by SPS, the 
sacrificial NaCl was dissolved in 1 M NaOH solution in vacuum desiccator 
[73]. The NaOH solution was exchanged periodically with ethanol as a buffer 
solution to prevent cracks and to rinse out the reaction products, such as 
Mg(OH)2.  
2.2.2. Fabrication of biomimetic porous Mg
Mg powder and NaCl powder were mixed with a small amount of 
ethanol. 70 vol% of NaCl powder was mixed with Mg powder to generate the 
high interconnectivity of the pores. Mixed powders were packed inside the 
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metal mold with different diameters (8 mm or 10 mm). 1 ton was pressed for 
5 min to compact Mg/NaCl mixed powders. Compacted powders were put in 
the center of carbon die with 12 mm inner diameter. Pure Mg powder was put 
around the compacted powders. Sintering and dissolving NaCl were 
performed in similar process as fabricating porous Mg as shown in Figure 2.2.
2.2.3. HA/PEI-Silica hybrid coating
For HA coating on porous Mg, an aqueous solution was prepared by 
dissolving ethylenediaminetetraacetic acid calcium disodium salt hydrate (Ca 
(EDTA), Sigma Aldrich, USA) and potassium phosphate monobasic (KH2PO4, 
Sigma Aldrich, USA) in distilled water to obtain concentrations of 0.25 mol/L 
each. The pH level of the solution was adjusted to 8.9 with NaOH solution, 
and the solution was heated to 90 °C inside a vacuum oven [56, 57]. To form 
an HA coating layer on the surface, the porous Mg was immersed in the 
solution for 3 h. 
Additionally, PEI-Silica hybrid layer was dual coated on HA coating 
layer. PEI solution was prepared by dissolving PEI pellets (Sigma Aldrich, 
USA) in 1-Methyl-2pyrrolidinone (NMP, Sigma Aldrich, USA) solvent by 15 
w/v%. In addition, for the reagent of silica sol, tetramethylorthosilane (TMOS, 
Sigma Aldrich, USA), distilled water, hydrochloric acid (1N, HCl, Alfa Aesar, 
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USA), and NMP were mixed at a volume ratio of 5 : 1 : 0.02 : 3. The NMP 
was added after the reaction of silica sol to prohibit phase separation between 
the PEI solution and silica sol during the preparation of the PEI-Silica hybrid 
solution. Silica sol was mixed with PEI solution at 15, 30, and 45 volume 
ratio of silica. PEI-Silica hybrid coating with 15, 30, and 45 vol% will be 
referred to as PEI-15% Silica, PEI-30% Silica, and PEI-45% Silica. At over 
45 vol% of silica, phase separation occurred while mixing the PEI solution 
and silica sol. Every solution was mixed in an oven at 37 °C to maintain the 
same mixing condition. After hybridization, HA coated porous Mg was 
immersed in each solution in vacuum desiccator. Solutions were put in the 
vacuum desiccator to immerse the solution inside the pores effectively. After 
coating process, specimens were dried in 70 °C dry oven for the dense PEI-
Silica hybrid coating layer with perfect evaporation of NMP. Scheme of the 
HA aqueous precipitation coating on porous Mg and PEI-Silica hybrid coating 
on HA coated porous Mg are shown in Figure 2.3.
2.2.4. Characterization of Mg scaffold
Microstructure and 3D structure were observed by SEM (JSM 6360, 
JEOL, Japan) and μ-CT (Skyscan 1173, Kontich, Belgium). Microtomography 
images were acquired at a resolution of 10 μm using a 1.0 mm aluminum filter. 
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The μ-CT scanner operated at 90 kV and 88 μA. The approximate porosity 
was calculated using measured mass (mS) and volume (VS)




                    (1)   
                 
where p is the total porosity in percentage, mS / VS is the measured density and 
ρMg is the theoretical density of the Mg.
Furthermore, porosity and pore size were also evaluated by processing 
the acquired μ-CT images using CTAn (Skyscan, Kontich, Belgium).
The phase analyses were performed by X-ray diffraction (XRD, D8-
Advance, BRUKER, Germany) with Cu Kα source and the scanning speed of 
1°/min.
2.2.5. Mechanical behavior of Mg scaffold
The mechanical properties of the fabricated Mg scaffolds were 
measured using an Instron 5582 System (Instron, Norwood, USA) under a 
displacement-controlled mode, with a cross-head speed of 1 mm/min. The 
four specimens used to examine the compressive strengths were 12 mm in 
diameter and 6 mm in height.
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2.2.6. Characterization of HA/PEI-Silica hybrid coating
The surface morphology and thickness of the HA, or HA/PEI or 
HA/PEI-Silica hybrid coating layers on porous Mg were observed by field-
emission scanning electron microscopy (FE-SEM, SUPRA 55VP, Carl Zeiss, 
Germany) and focused ion beam (FIB, AURIGA, Carl Zeiss, Germany)
respectively. The distribution and the particle size of the silica were observed 
with a transmission electron microscope (TEM, JEM-2100F, JEOL, Japan). 
To observe the particles with TEM, PEI-Silica hybrid the solution was spin-
coated on the copper grid (400 mesh, TED PELLA Inc., USA). The chemical 
structures of the hybrid coating layers were evaluated by Fourier transform 
infrared spectroscopy (FT-IR, Nicolet 6700, Thermo Scientific, USA). 
Moreover, the hydrophilicity of the coating layers was examined by observing 
the contact angle of the distilled water droplet using the Phoenix 300 contact 
angle analyzer (surface Electro Optics Co. Ltd, Korea). Six specimens were 
tested for each coating condition.
2.2.7. In-vitro corrosion behavior evaluation
The corrosion behavior was evaluated by monitoring the amount of 
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hydrogen gas evolved after immersing bare porous Mg or HA, HA/PEI or 
HA/PEI-Silica hybrid (15 and 30 vol%) coated porous Mg in 80 ml of 
simulated body fluid (SBF) at 37 °C. The specimens were in a diameter of 12 
mm and a thickness of 1.5 mm. Three specimens were tested for each 
condition. The SBF was prepared using the method proposed by Kokubo et al 
[74].
2.2.8. In-vitro biological behavior evaluation
The initial cell adhesion of the pre-osteoblast cell (MC3T3-E1, 
ATCC, CRL-2593, USA) was performed. Every specimen was cleansed in 70% 
ethanol and dried for 24 hours in a vacuum chamber. After drying the 
specimens, they were placed on a clean bench for 1 hour for sterilization with 
ultraviolet light. The cells were cultured in an alpha minimum essential 
medium (α-MEM, Welgene, USA) supplemented with 5% fetal bovine serum 
(FBS, Gibco, USA) and 1% penicillin-streptomycin (Pen strep, Gibco, USA) 
in a humid incubator with 5% CO2 at 37 °C. 
The initial cell attachment was observed with SEM after 6 hours of 
cell seeding with the density of 5 × 104 cells/ml on HA or HA/PEI-Silica (0, 
15 or 30 vol%) hybrid coated porous Mg. The SEM specimens were prepared 
by immersing in 2.5% glutaraldehyde (Sigma Aldrich, USA) for 10 min, 
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dehydrating in graded ethanol (70, 90, 95, and 100% ethanol in sequence) and 
finally immersing in hexamethyldisilazane (Sigma Aldrich, USA) for 10 min. 
2.2.9. In-vivo biodegradation and bone response 
evaluation
New Zealand white rabbits (3-month-old males weighing 3.0–3.5 kg) 
(Kosabio, Korea) were used to evaluate the in-vivo biodegradation and bone 
response of the HA, HA/PEI or HA/PEI-15% Silica coated biomimetic porous 
Mg. In-vivo animal experiment was conducted using the rabbit femoropatellar 
groove model in accordance with the procedure reported in the literature [75].
All rabbits were anesthetized through intramuscular injection of a 
combination of 0.1 mL of 2% Xylazine HCl (Rompun, Bayer Korea, Korea), 
0.2 mL of Tiletamine HCl (Zoletil, Virbac Laboratories, France), and 
Lidocaine (Yuhan Corporation, Korea). After anesthetization the patella was 
dislocated laterally and the surface of the femoropatellar groove was exposed. 
A full-thickness cylindrical cartilage defect (5 mm in diameter, 4 mm in depth) 
was created in the patellar groove. The HA, HA/PEI or HA/PEI-15% Silica 
coated biomimetic porous Mg which had similar structure of the natural bone 
were implanted in the cartilage defects as shown in Figure 3.4.
At 5 weeks after the implantation, the rabbits were sacrificed to 
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extract the regions of bone defect. To evaluate new bone formation, the 
harvested bone tissues were scanned by μ-CT with 1.0 mm aluminum filter at 
a resolution of 17 μm, a voltage of 90 kV and a current of 88 μA. The cross 
section images of the specimens and bone tissues were obtained using post 
processing software (Data Viewer 1.4). The bone regeneration volume was 
evaluated by processing the acquired μ-CT images using CTAn. Three
specimens were examined to obtain the mean value and standard deviation. 
2.2.10. Statistical analysis
All data are expressed as mean ± standard deviation (SD). The 
statistical analysis was performed by one-way analysis of variance with 
Bonferroni's post-hoc comparison. A p value inferior to 0.05 was considered 
statistically significant in all cases.
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2.3. Results and discussion
2.3.1. Physical and chemical structure of porous Mg
Figure 2.5. shows the typical optical image of porous Mg with 
different porosities (50%, 60% and 70% porosity). The porosity of Mg was 
well controlled by volume contents of NaCl. No signs of carbonization were 
observed after the SPS and pore generating process. This suggests that SPS 
and space holder method are effective to fabricate porous Mg scaffolds with 
various porosities. However, porosity of Mg scaffold was limited from 50 to 
70% due to the shape of the pore generator and the mechanical strength of Mg.
It should be noted that as the porosity decreases lower than 50% the amount 
of NaCl which is not eliminated during the pore generating process increases. 
Moreover, the porous Mg with porosity higher than 70% had thin Mg struts 
which results in low mechanical strength. 
Figure 2.6. shows the SEM images of the porous Mg scaffolds with 
various porosities (70, 60, and 50 vol.%). The Mg scaffolds showed large 
pores with good pore interconnectivity, while Mg particles were fully 
densified without any noticeable pores or defects, showing that SPS allowed 
for the achievement of full densification of Mg walls, which would be hardly 
obtainable using conventional techniques to fabricate porous Mg [62, 64, 76-
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79]. 
A cross-sectional m-CT image of the specimens showed a uniform 
distribution of pores with high pore interconnectivity shown as Figure 2.7. 
White dots indicate NaCl remained after pore generating process. Amount of 
the remained NaCl increased as the porosity decreased due to the increase of 
the closed pores. The porosity and the pore sizes of each specimen were 
calculated using the program and provided a calculated porosity similar with 
the porosity according to Eq. (1). The pore size of the specimens was 240 μm 
in average, indicating their suitability for osteoconduction upon implantation 
[80, 81].
Figure 2.8. shows the XRD patterns of Mg/NaCl composite with 60 
vol% of NaCl after sintering and porous Mg after dissolving NaCl. XRD
patterns mainly displayed peaks corresponding to Mg and NaCl for Mg/NaCl 
composite but not NaCl peaks for porous Mg. This suggests that NaCl 
particles were properly removed in the presence of NaOH [73]. Moreover, 
dominant peaks of oxidized or carbonized Mg were not found on the XRD 
pattern, indicating the oxidation or carbonization which occurs easily during 
general sintering process did not occur during SPS.
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2.3.2. Mechanical behaviors of porous Mg
The mechanical properties of the bare porous Mg with different 
porosities (50%, 60% and 70%) were evaluated by compression tests. Typical 
stress–strain diagrams for the porous Mg specimens with various porosities 
are shown in Figure 2.9. All porous specimens produced exhibited ductile 
behavior under compression, demonstrating the suitability of the SPS 
technique for densifying Mg compacts without the oxidation and 
carbonization of Mg powders. Figure 2.10. shows the average ultimate 
compressive strength and stiffness of the porous Mg with various levels of 
porosity (50%, 60% and 70%). The average ultimate compressive strengths of 
porous Mg with 50%, 60% and 70% porosity were 30 MPa, 15 MPa and 7 
MPa, respectively, and the average elastic modulus were 0.49 GPa, 0.33 GPa, 
and 0.23 GPa, respectively. These values are compatible with those for human 
cancellous bone [1] and comparable with those reported in the literature [62, 
64]. 
2.3.3. Physical structure of biomimetic porous Mg
Figure 2.11. shows the typical optical image of biomimetic porous 
Mg with different ratio of dense/porous structure, resulting in different total 
porosity (70%, 49% and 31% porosity). The ratio of dense/porous structure 
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was controlled by controlling the volume of Mg/NaCl compact before 
sintering. 70% porosity was selected for the porous structure for the high 
interconnectivity of the pores. The final structure was hierarchical, with two 
different dense and porous structure, resembling the structure of a bone [82-
84].
Figure 2.12. shows the SEM images of the interface of dense/porous 
structure, and high magnification of each dense and porous structure of the 
biomimetic porous Mg. From the low magnification, porous structure had
large pores with good pore interconnectivity similar with that of the porous 
Mg with 70% porosity. Moreover, the interface between the two structures
remained intact during the sintering step. By high magnification of each dense 
and porous structure, it was found that Mg particles were fully densified 
without any noticeable pores or defects by SPS.
A cross-sectional m-CT image of the specimens showed a uniform 
distribution of pores with high interconnectivity as shown in Figure 2.13. 
Moreover, cross-sectional images and 3D reconstructed images showed 
similar structure of biomimetic porous Mg with that of the natural bone. The 
porosity and the pore sizes of each specimen were calculated using the 
program and the total porosity of the Mg scaffold had similar with the 
porosity according to Eq. (1). Furthermore, porous structure had average pore 
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size of 240 μm similar with the porous Mg due to the same size of NaCl space 
holder.
2.3.4. Mechanical behaviors of biomimetic porous Mg
The compressive stress-strain curve and compressive mechanical 
behaviors of the biomimetic porous Mg with different ratio of the 
dense/porous structure were evaluated (Figure 2.14. and Figure 2.15.). The 
ultimate compressive strength and stiffness of biomimetic porous Mg with 
70%, 49% and 31% porosity were 4 MPa, 15MPa and 71 MPa, and 0.13 GPa, 
0.42 GPa and 0.67 GPa respectively. The enhanced compressive strength was 
mainly attributed to the increase in the portion of the dense structure. By 
controlling the dense/porous ratios of the scaffolds, the structural and 
compressive features can be customized to match those of the surrounding 
bones at the implant site [85, 86]. The compressive strengths of fabricated 
biomimetic porous Mg scaffolds with bone-like structures were within the 
range of 15–70 MPa, which are in the range of those in tibia, femur, and 
trabecular bone, with or without marrow [86, 87].
2.3.5. Morphology and chemical structure of HA/PEI-
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Silica coating layers
A dense HA layer comprised of needle-shaped HA crystals with a 
thickness of ~2 μm of was formed uniformly on the surfaces of porous Mg 
(Figure 2.16. (a, f)) [61]. In addition, surface morphologies of pure PEI and 
PEI-Silica hybrid coating layers which were dual coated on HA layer are 
shown in Figures 2.16. (b)–(e). The pure PEI, PEI-15% Silica, and PEI-30% 
Silica hybrid coating layers were found to cover the HA coating layer
homogenously. On the other hand, on the surface of the PEI-45% Silica 
coating layer, a small number of cracks appeared occasionally (Figure 2.16. 
(e)). The hybrid coating layer with silica >45 vol% was found to have the 
greater number of cracks as the silica content increased, failing to cover the 
entire Mg surface [88]. The representative cross-section image of HA/PEI-
Silica hybrid coated porous Mg is shown in Figure 2.16. (f). Some of the 
cracks were found on the HA layer propagating to the surface of porous Mg. 
However, dense PEI-Silica hybrid layer was completely covering the cracks 
of HA coating layer. Even though the viscosity of hybrid sols had decreased 
with the increased amount of silica sol, the coating thickness of the PEI or 
PEI-Silica layers was almost identical under the current dip coating and 
drying conditions. Moreover, the vacuum state during the dip coating allowed
the good infiltration of pure PEI or PEI-Silica into the nano-roughened HA 
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surface. Due to the nanoscale roughness of HA, interfacial surface area 
between HA and polymer increased resulting in a strong bonding between two 
layers.
The high resolution TEM image and EDS pattern in Figure 2.17.
show the silica nanoparticles embedded in the PEI matrix for PEI-15% Silica. 
The size of silica nanoparticles was 50–300 nm and the degree of 
agglomeration was low, avoiding prominent clusters. Therefore, it was 
confirmed that the sol–gel method could produce homogeneous PEI-Silica 
hybrid systems with minimal agglomeration of the silica phase. Above 45 vol% 
of silica, the PEI-Silica coating layers became brittle due to the relatively 
large contents of silica [71]. Therefore, during the drying process, the 
solidified hybrid coating layer with higher silica contents (>45 vol%), in 
which the silica phase became dominant in the hybrid systems, contained 
significant surface cracks due to induced stresses within the coating layer, 
often caused by the volume contraction of the coating constrained by the 
underneath substrate [89]. Therefore, in this study, PEI-15% Silica and PEI-30 
vol% Silica were chosen for crack-free and homogeneous hybrid coating 
layers on HA layer, after comparison with the pure PEI coating. 
Figure 2.18. shows the FT-IR spectrum of pure PEI or PEI-Silica 
hybrid (15 and 30 vol %) coating layers on Mg. Main peaks at 1778 and 1720 
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cm−1 were detected, corresponding to the symmetric and asymmetric 
stretching vibration of C = O groups. The peak at 1353 cm−1 was related to the 
symmetric stretching of C–N–C in the imide ring [46]. Moreover, the 900–
1200 cm−1 peaks indicated overlapping of the asymmetric stretching 
vibrations of the siloxane groups (Si–O–Si) and silanol groups (Si–OH) [90]. 
In the case of the PEI-Silica hybrids, the intensity of the 900–1200 cm−1 peaks 
became stronger as the silica content increased because of the larger amount 
of silica bonding. Besides the PEI or silica-related characteristic peaks, no 
significant peaks were observed, implying that the PEI and silica maintained 
their inherent properties without any significant deterioration due to the 
undesirable reactions between PEI and silica.
2.3.6. Hydrophilicity of HA/PEI-Silica coating layers
Hydrophilic materials have previously been incorporated with a 
relatively hydrophobic polymer matrix in order to improve the hydrophilicity 
of the matrix for enhanced biodegradability and better cell affinity of coated 
Mg [71, 72, 91]. Thus, the contact angle was measured to observe the silica 
influence on wettability of PEI as shown in Figure 2.19. The HA coated Mg 
was highly hydrophilic showing the contact angle nearly 0°. HA has large 
amount of hydroxyl functional groups resulting in highly hydrophilic [92]. 
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After dual coating with pure PEI, contact angle increased about to 65°. As the 
amount of silica increased from 15 vol% to 30 vol%, the equilibrium contact 
angle gradually decreased from about 58° to about 52°, and the water droplet 
on the surface of hybrid coating layers became more spread as the silica 
content increased. Therefore, the incorporation of silica clearly improved 
hydrophilicity of PEI-Silica hybrid coatings.
2.3.7. In-vitro corrosion behavior of HA/PEI-Silica 
coated porous Mg
Corrosion tests with porous Mg specimens coated with HA, HA/PEI 
and HA/PEI-Silica (15 and 30 vol% silica) were performed by immersing 
these specimens in SBF, compared to bare porous Mg (Figure 2.20.). One of 
the major outcomes from the corrosion reaction of Mg (H2 gas generation), 
were monitored as indicators of Mg corrosion. Bare Mg corroded the most 
rapidly, generating the highest volume of hydrogen gas, whereas coating on 
porous Mg decreased the corrosion rate of porous Mg. However, by dual 
coating pure PEI or PEI-Silica hybrid on HA layer further decreased the 
corrosion rate and increasing the stability of the porous Mg. PEI dual coated 
porous Mg corroded the least with a minimal generation of H2 gas generation. 
The corrosion behavior of the hybrid coated Mg fell between that of HA 
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coated porous Mg and HA/PEI dual coated porous Mg, varying with the 
amount of incorporated silica. The removal of silica through the dissolution 
process in SBF might create nano-sized voids within the PEI matrix which, in 
return, were filled with water, creating the penetration path of water to the 
underneath porous Mg. The incorporation of silica nanoparticles in the PEI 
coating clearly increased the corrosion rate of Mg substrate underneath the 
coating layer. Zomorodian et al [93] also found that HA nanoparticles in the 
PEI coating decreased the corrosion resistance of Mg alloys due to the 
decreased pore resistance in the coating layer. The increased porosity of the 
coating layer can likely be attributed to the fast dissolution of the silica 
nanoparticles. Moreover, the number of pores controlled by the silica content 
positively correlated with the corrosion rate of Mg. Furthermore, the 
improved hydrophilicity of the PEI coating due to silica might contribute to 
the increased corrosion rate of Mg. The improved water accessibility to the 
relatively hydrophilic surface of hybrid coating could enhance the diffusion of 
water through the coating layer, compared to the pure PEI coating surface.
However, all pure and hybrid dual coatings were found to significantly reduce 
the released volume of H2 gas generated from porous Mg compared to HA 
coated porous Mg (Figure 2.20.), showing the good corrosion resistance by 
dual coating.
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2.3.8. In-vitro biological behavior of HA/PEI-Silica 
coated porous Mg
The initial cell morphology on the HA/PEI-Silica hybrid coated Mg 
were evaluated and compared to the both HA coated porous Mg and HA/PEI 
coated porous Mg. Figures 2.21. shows the early-stage morphology of the 
MC3T3-E1 cells after 24 h cell culturing on porous Mg specimens coated 
with HA, HA/PEI or HA/PEI-Silica hybrid (15 and 30 vol%). On the HA 
coated porous Mg, only a few cells were attached, with an almost round shape 
with minimal spreading (Figures 2.21. (a)). The poor cell attachment of HA 
coated porous Mg has been attributed to the rapid pH increase and H2
evolution during corrosion [29, 50, 93]. However, the cells were strongly 
attached to the HA/PEI and HA/PEI-Silica coated porous Mg surfaces as 
shown in Figures 2.21. (b)-(d). Importantly, the cells became more spread out 
and flattened on the HA/PEI-Silica hybrid coating layer than those on the 
HA/PEI coating layer. The relatively hydrophilic character of hybrid coating 
likely improved the cell affinity of the surface, promoting cell attachment at 
the early stage of cell growth, besides the effect of the released Mg and Si 
ions from the corroded Mg [71, 72, 88, 91]. The in-vitro cell tests clearly 
demonstrated that PEI-Silica hybrid coating layers could enhance the 
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biological performance of the HA coated porous Mg implants compared to the 
PEI coating, mainly due to the increased hydrophilicity and amount of Mg 
and Si ions. It is known that the appropriate amount of Mg or Si ions can 
improve cell attachment, proliferation, and differentiation [71, 94, 95]. 
2.3.9. In-vivo biodegradation and bone response 
HA, HA/PEI or HA/PEI-15% Silica coated biomimetic porous Mg 
which had similar structure with that of the natural bone were implanted into 
rabbit femoropatellar defects to closely evaluate their bone responses. After 5 
weeks of healing, the specimens and surrounding bone tissues were extracted 
as shown in Figure 2.22. New tissues formed on the top of the HA/PEI-15% 
Silica coated biomimetic porous whereas some of HA coated and HA/PEI 
coated specimen were not covered with the new tissues. The morphology of 
the implanted specimens and the new bone formation were observed with m-
CT. Figure 2.23. shows representative cross-sectional image of the specimens 
and surrounding bone tissues. The gray and white represent the Mg specimen 
and the original bone tissue regions, respectively. Specimens with different 
coatings exhibited different degradation rates. In the case of HA coated and 
HA/PEI-15% Silica coated specimen, corrosion occurred faster than HA/PEI 
coated specimen after 5 weeks of implantation showing some collapse of the 
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structure. This result had similar trend with the result of in-vitro corrosion test 
in Figure 2.20. However, the HA/PEI-15% Silica coated specimen exhibited 
the better formation of new bone near the defect boundaries and bone 
ingrowth towards the inner part of the scaffolds to some extent. Furthermore, 
the new bone volume was measured by m-CT analysis. Figure 2.24 shows the 
new bone volume formed inside the pores of the biomimetic Mg. Similar 
result with the cross-sectional m-CT images, the HA/PEI-15% Silica coated 
specimen exhibited the higher volume of bone regeneration inside the pores of 
the specimen compared with HA, HA/PEI coated specimens. It can be stated 
that the HA/PEI-15% Silica coated biomimetic Mg showed the highest extent 
of bone ingrowth, which demonstrates the efficacy of HA/PEI-Silica hybrid
coating as a means of decreasing the corrosion rate than HA coating and 
promoting bone regeneration than HA/PEI coating. These results are in 
agreement with earlier studies where a bioactive silica hybridized-coating 
layer was reported to promote bone-implant interaction and lead to a good 
contact with the surrounding bone tissue [96]. Improvement of bio-corrosion 
resistance, biocompatibility and bone response on biomimetic porous Mg 
achieved in this work through coating with HA/PEI-Silica gives promise for 
greater acceptance of Mg implants in biomedical industry.
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2.4. Conclusions
In this study, we fabricated biomimetic porous Mg mimicking the 
structure of the bone by the spark plasma sintering of Mg powder blended 
with NaCl powder, which served as a sacrificial space holder. The biomimetic 
porous Mg obtained after the dissolution of the NaCl particles possessed good 
mechanical properties and a pore structure with high interconnectivity of the 
pores that qualifies the materials for applications in dental and orthopedic 
implants. Furthermore, the bio-corrosion of porous Mg was significantly 
inhibited by HA/PEI-Silica coating. HA coating decreased corrosion rate of 
porous Mg, however, due to the brittle characteristic of HA, cracks formed on 
the coating layer and acted critically to the corrosion of porous Mg. As a 
result, homogeneous PEI-Silica hybrid materials were successfully fabricated 
with various silica contents using the sol–gel method, and were dual coated on 
HA coated porous Mg by dip coating process. The 50–300 nm sized silica 
nanoparticles were well dispersed in the PEI matrix without significant 
particle agglomeration up the 30 vol% silica. The corrosion rate remarkably 
decreased by dual coating pure PEI or PEI-Silica hybrid on HA coated porous 
Mg compared with bare and HA coated porous Mg. Moreover, the 
biocompatibility of the HA/PEI-Silica hybrid coated porous Mg specimens 
were significantly improved, mainly due to the higher hydrophilicity and Mg 
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and Si ion concentrations associated with faster corrosion compared to the 
HA/PEI dual coated porous Mg. Therefore, PEI-Silica hybrid systems have 
considerable potential as a coating material of Mg for dental and orthopedic 
applications by providing enhanced corrosion resistance and biological 
performance.
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Figure 2.1. Scheme of the structure and coating layer of PEI-Silica dual 
coated biomimetic Mg
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Figure 2.2. Experimental procedure of fabricating Mg with (a) porous 
structure and (b) biomimetic structure
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Figure 2.3. Experimental procedure of (a) aqueous precipitation coating of 
HA on porous Mg and (b) dip coating PEI-Silica hybrid on HA coated porous 
Mg by sol-gel method
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Figure 2.4. In-vivo rabbit femoropatellar groove model experiment (a) before 
implantation and (b) after implantation of biomimetic porous Mg; cross 
sectional m-CT image of (c) natural femoropatellar bone and (d) biomimetic 
porous Mg
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Figure 2.5. Optical images of porous Mg with 70%, 60%, and 50% porosity 
fabricated by SPS and space holder method
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Figure 2.6. SEM images of porous Mg with (a. d) 70%, (b. e) 60%, and (c, f) 
50% porosity in low and high magnification respectively
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Figure 2.7. Cross sectional m-CT images of porous Mg with (a) 70%, (b) 60%, 
and (c) 50% porosity
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Figure 2.8. XRD patterns of Mg/NaCl composite after SPS and after 
dissolving NaCl
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Figure 2.9. Stress-strain curve of porous Mg with different porosity (50%, 
60%, and 70%)
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Figure 2.10. Ultimate compressive strength and stiffness of porous Mg with 
different porosity (50%, 60%, and 70%)
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Figure 2.11. Optical images of biomimetic porous Mg with (a) 70%, (b) 49%, 
and (c) 31% porosity
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Figure 2.12. SEM images of (a) interface of dense/porous structure, and high 
magnification of (b) dense structure and (c) porous structure of biomimetic 
porous Mg 
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Figure 2.13. Cross sectional m-CT images of biomimetic porous Mg with (a) 
70%, (c) 49%, and (e) 31% porosity and 3D reconstructed structure of 
biomimetic porous Mg with (b) 70%, (d) 49%, and (f) 31% porosity
57
Figure 2.14. Stress-strain curve of biomimetic porous Mg with different 
porosity (31%, 49%, and 70%)
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Figure 2.15. Ultimate compressive strength and stiffness of biomimetic 
porous Mg with different porosity (31%, 49%, and 70%) and dense bulk Mg
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Figure 2.16. Surface SEM images of (a) HA, (b) HA/PEI-0% Silica, (c) 
HA/PEI-15% Silica, (d) HA/PEI-30% Silica and (e) HA/PEI-45% Silica 
coated porous Mg, and cross sectional image of (f) HA/PEI-15% Silica coated 
porous Mg
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Figure 2.17. (a) TEM image, and (b) EDS patterns of silica nano particles 
dispersed in PEI matrix
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Figure 2.18. FT-IR transmission spectrum of (A) pure PEI, (B) PEI-15% 
Silica and (C) PEI-30% Silica coating layers on Mg surface
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Figure 2.19. Water contact angle on HA, and HA/PEI-Silica (0 vol%, 15 vol% 
and 30 vol%) dual coated Mg (**p < 0.005)
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Figure 2.20. Volume of H2 gas evolution after immersing bare, HA, and 
HA/PEI-Silica (0 vol%, 15 vol%, and 30 vol%) dual coated Mg in SBF
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Figure 2.21. Initial MC3T3-E1 cell attachment on (a) HA, (b) HA/PEI-0% 
Silica, (c) HA/PEI-15% Silica, and (d) HA/PEI-30% Silica coated porous Mg 
after 6 hours culturing (arrows indicating cells)
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Figure 2.22. Representative rabbit femoropatellar images retrieved 5 weeks 
after implanting (a) HA coated, (b) HA/PEI coated and (c) HA/PEI-15% 
Silica coated biomimetic porous Mg
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Figure 2.23. Cross-sectional m-CT images of a representative rabbit 
femoropatellar bone after 5 weeks, (a) HA coated, (b) HA/PEI coated and (c) 
HA/PEI-15% Silica coated biomimetic porous Mg
67
Figure 2.24. The new bone volume generated from HA coated, HA/PEI 
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Conventional bare metal stents (BMS) and drug eluting stents (DES) 
are mostly made of non-biodegradable materials. However, these non-
biodegradable stents have problems such as stent migration due to the growth 
of blood vessels for pediatric patients, permanent physical irritation, limitation 
of re-stenting in identical site and late thrombosis [97-99]. Biodegradable 
stent could be the solution to these problems since it would be fully absorbed 
after the widening of the narrowed blood vessel and recovery of the damaged 
tissues [3, 97, 99].
Magnesium (Mg) and its alloys have been regarded as promising 
biodegradable stent materials. Mg has higher mechanical strength compared 
to other biodegradable polymers which enables to fabricate stents having high 
strength despite of the thin struts [100-103]. Furthermore, Mg is one of the 
essential elements used in human metabolism and it accelerates proliferation 
of endothelial cells [104-106]. However, rapid corrosion of Mg in
physiological environments has limited the use of Mg in clinical applications. 
When rapid corrosion occurs, mechanical strength deteriorates severely, 
resulting in the stent collapse before the revascularization. Moreover, massive 
hydrogen gas generation and pH increase during the corrosion prohibit the 
endothelial cell attachment and proliferation, even worse, cause inflammatory 
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responses [107]. 
To protect Mg from rapid corrosion, various surface modifications 
such as micro arc-oxidation, anodization, fluoride or phosphate treatment, ion 
implantation and polymer coating were performed [1, 42, 46, 50, 54]. Among 
the various surface modifications, biodegradable polymer coating is beneficial 
for the stent application due to the corrosion protection and also its flexibility 
and stable drug release behavior. Because stents are expanded inside the blood 
vessel, coating material should be flexible to prevent delamination or crack 
formation during the expansion of the stent [100, 108]. Moreover, stents are 
often required to release anti-proliferative drugs such as paclitaxel or 
sirolimus to prohibit restenosis [100, 108-111]. Therefore, poly(lactic-co-
glycolic acid) (PLGA) was coated on Mg as a corrosion protective drug 
carrier because of its considerable degradation rate and biocompatibility [112-
115]. However, PLGA provided insufficient corrosion protection because of 
the low adhesion strength to Mg [116, 117]. Delamination of the polymer 
coating occurred during the corrosion results in the exposure of Mg which 
accelerates the corrosion. To prevent the delamination of the coating layer, 
polyetherimide (PEI) can be a great candidate for Mg stent coating material 
due to the good adhesion strength on Mg, additionally good biocompatibility 
with the endothelial cell [118]. However, because PEI is not suitable for the 
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drug release layer due to the high chemical stability, additional drug loaded 
polymer coating layer is necessary. 
Therefore, PLGA loaded with anti-proliferative drug can be 
additionally coated on PEI coated Mg stent for the reliable drug release. Drug 
loaded in PLGA would restrain the rapid growth of smooth muscle cell [112, 
114]. However, anti-proliferative drug could also prevent revascularization by 
prohibiting the attachment and proliferation of endothelial cell on the luminal 
area of the stent. Therefore, drug loaded PLGA layer should be only exposed 
to the abluminal area of the stent which is in contact with the blood vessel and 
only PEI layer should be exposed to the luminal area of the stent to accelerate 
the revascularization by restraining the rapid corrosion of Mg stent. 
Furthermore, due to the decrease of the corrosion rate PLGA layer would be 
stably attached to the Mg stent and the drug would be released stably. Figure 
3.1. shows scheme of the selective PEI/PLGA dual coating on Mg stent and 
the main purpose of each coating layers.
In this study, gradually coated PEI and drug loaded PLGA dual layer 
is demonstrated as the coating material for Mg stent application. WE43 stent 
was selectively dual coated with PEI/PLGA and coating morphology was 
observed after expansion of the stent. To evaluate the corrosion protection of 
the coating layer dynamic corrosion test was performed on the condition 
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mimicking the blood flow and the structure and volume of the stent was 
evaluated with m-CT. To evaluate release behavior of sirolimus and biological 
behavior of PEI/PLGA dual layer for the Mg stent coating, dual layer was 
spin-coated on Mg substrate. The release behavior of sirolimus which was 
loaded in dual coating layer was examined with UV spectrometer. Lastly, 
biological cell response on the coated specimens was examined by culturing
human vascular endothelial cell (HUVEC) and vascular smooth muscle cell 




WE43 Mg alloy (4.51 wt% yttrium, 2.05 wt% neodymium, 0.31 wt% 
zirconium, 0.051 wt% calcium, 0.011 wt% manganese, and balance Mg) 
specimens were prepared with the dimensions of 10 mm × 10 mm × 2 mm 
from commercial extruded WE43 Mg alloy supplied by commercial vendor 
(Yueyang Yuhua Yejin company, Beijing, China). The Mg specimens were 
polished with abrasive SiC papers from 400 to 1200 grit, and subsequently 
were cleansed with ethanol in an ultrasonic bath. PEI solution for coating 
material was prepared by dissolving PEI pellets (Sigma Aldrich, USA) in 1-
Methyl- 2pyrrolidinone (NMP, Sigma Aldrich, USA) solvent by 15 w/v%.
PLGA solution for coating material was prepared by dissolving PLGA pellets 
(lactide : glycolide = 65 : 35, Mw = 40,000-75,000, Sigma Aldrich, USA) in 
Tetrahydrofuran (THF, Sigma Aldrich, USA) solvent by 7.5 w/v%. PLGA was 
dissolved in THF to prevent the undesirable reaction and dissolution of PEI 
during dual coating PLGA on PEI coating layer. Pure PEI or PLGA were 
coated on Mg substrate by spin-coating at 3000 rpm for 1 min. The PEI 
coated specimen and PLGA coated specimen were dried at 70 °C and 37 °C 
respectively after spin coating for the dense PEI and PLGA coating layer with 
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perfect evaporation of the solvent. PEI/PLGA dual coating was performed by 
spin coating PEI on Mg substrate and spin coating PLGA on PEI coated Mg
in sequence. PEI was fully dried in 70 °C oven for 1 day before PLGA dual 
coating and PLGA dual coated specimen was dried in 37 °C. For the drug 
loaded PLGA layer, sirolimus was dissolved in PLGA/THF solution by 3wt% 
and the solution was spin coated on PEI coated Mg specimen in the similar
condition.
WE43 Mg alloy stent with a 15 mm length, 2 mm in diameter, and 150 
mm strut thickness (Genoss, Korea) was prepared. PEI, PLGA or selective 
PEI/PLGA coating was performed by spray coater (Sonicoater, NOANIX, 
Korea). Mg stent was fixed at the end of the spray coater jig and PEI or PLGA 
was spray coated by the conditions shown in Table 3.1. Various parameters 
can be controlled during spray coating. Concentration of the polymer solution, 
distance from the stent and the spray nozzle, pressure of N2 gas to spray the 
solution droplets, injection speed of the polymer solution, rotation speed of 
the stent and moving speed of the jig to the lateral way can be controlled. PEI 
and PLGA was spray coated 4 times each and coated stent was dried in 70 °C 
and 37 °C for 1 hr before every additional spray coating, respectively. 
Selective abluminal coating was performed by inserting the stent fully inside 
the jig. Figure 3.2. shows experimental procedure of selective PEI/PLGA dual 
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coating on Mg stent.
3.2.2. Characterization of selective PEI/PLGA coating
The surface morphology and thickness of the selective PEI/PLGA 
coating layers on Mg stent were observed by scanning electron microscopy 
(SEM, JSM-6360, JEOL, Japan) and focused ion beam (FIB, AURIGA, Carl 
Zeiss, Germany). Surface of the coated stent was observed after expansion in 
PBS (Welgene, Korea) at 37 °C. Scratch test was performed on PLGA or 
PEI/PLGA coated WE43 substrate with micro scratch tester (APEX-2T, 
Bruker, Germany). The velocity of the indenter was 2.5mm/s and the scratch 
distance was 500 mm.
3.2.3. In-vitro dynamic degradation test
Dynamic degradation tests were conducted by the experimental 
procedure designed to mimic the environment encountered by coronary stents 
with a constant laminar flow [119]. Simulated body fluid (SBF) was chosen as 
a circulating solution due to its stability and similar ion composition as human 
blood plasma [74]. PLGA or selective PEI/PLGA WE43 stent was expanded 
inside silicon rubber tubing (DAIHAN, Korea) with 3mm inner diameter in 
SBF solution at 37 °C after 1 min of stabilization. SBF solution was circulated 
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by the speed of 1 mL/min. At each predetermined period (0, 3, 7 and 14 days) 
3D structure of the Mg stents were observed by μ-CT (Skyscan 1173, Kontich, 
Belgium). Furthermore, volume of the stent was measured using CTan 
software (Skyscan 1173, Kontich, Belgium).
3.2.4. Release behavior of sirolimus from PEI/PLGA 
coated Mg
Sirolimus loaded PLGA or PEI/PLGA dual coated Mg were immersed 
in PBS at 37 °C. The stability of drug loaded coating layer was observed by 
SEM. Specimens were taken out after 1 d immersion in PBS and rinsed with 
distilled water before SEM observation.
To quantify the amount of sirolimus loaded in coating layer, specimens 
were immersed in 5 mL of methylene chloride (MC, J.T.Baker, USA) and 
vortexed for 3 hours. After vortexing, the MC was fully evaporated in vacuum 
desiccator. 10 mL of methanol (J.T.Baker, USA) was added and vortexed for 1 
min to dissolve sirolimus in methanol. Subsequently, 1ml of methanol was 
extracted with the syringe and absorbance values of sirolimus dissolved 
methanol was measured by UV spectroscopy at 278 nm, and then converted 
by a calibration curve. The calibration curve was prepared by measuring the 
optical absorbance values of sirolimus in 0.1-50 mg/mL methanol. The 
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obtained curve showed a linear relationship between the absorbance values 
and sirolimus concentration. Thus, each absorbance value was directly 
converted to the amount of sirolimus in each solution.
The release behavior of sirolimus was also monitored using UV 
spectroscopy by measuring the absorbance values of the released sirolimus at 
278 nm. The sirolimus loaded PLGA or PEI/PLGA dual coated Mg were 
immersed in 3 mL of PBS with 0.05% of Tween20 (Sigma, USA) at 37 °C. 
The sirolimus released solutions were extracted at predetermined time and 
replaced with fresh PBS with 0.05% of Tween20. Prior to measuring optical 
absorbance values of the extracted solutions, the extracted solutions were 
mixed with 3 mL of MC and vortexed for 1 hour and MC was extracted with 
the syringe to the new vial and the MC was fully evaporated for 1 day. 
Subsequently, 3 mL of methanol was added and vortexed for 1 min to dissolve 
sirolimus remained in the vial. Absorbance values of sirolimus dissolved in 
methanol was measured by UV spectroscopy at 278 nm, and then converted 
by a calibration curve.
3.2.5. In-vitro biocompatibility test
To mimic the luminal surface of the stent, the initial cell adhesion and 
proliferation of human umbilical cord vein endothelial cells (HUVECs; ATCC, 
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CRL-1730) were performed. HUVECs were seeded on bare, PLGA or PEI 
coated Mg substrate as shown in Figure 3.10 (a). Furthermore, in-direct effect 
of sirolimus loaded on PLGA coating layer at abluminal surface to luminal 
surface of the stent was evaluated by the initial cell adhesion and proliferation 
of HUVEC. Cells were seeded on PEI coated Mg surface with PEI/PLGA 
dual coating on the bottom side of the specimen. Biological behaviors were 
compared depending on the existence of sirolimus in PLGA layer as shown in 
Figure 3.12 (a). To mimic the abluminal surface of the stent and evaluate the 
direct-effect of sirolimus, the initial cell adhesion and proliferation of vascular 
smooth muscle cell (VSMC, LONZA, CC-2583, Switzerland) were performed. 
VSMCs were seeded on PEI/PLGA dual coated Mg substrate and biological 
behaviors were evaluated depending on the existence of sirolimus in PLGA 
coating layer as shown in Figure 3.14 (a). Every specimen was cleansed in 70% 
ethanol and dried for 24h in a vacuum chamber. After drying the specimens, 
they were placed on a clean bench for 1 hour of sterilization with ultraviolet 
light. The cells were cultured in an alpha minimum essential medium (α-
MEM, Welgene, USA) supplemented with 5% fetal bovine serum (FBS, 
Gibco, USA) and 1% penicillin-streptomycin (Pen strep, Gibco, USA) in a 
humid incubator with 5% CO2 at 37 °C. The initial cell attachment was 
observed with confocal laser scanning microscope (CLSM, Fluoview FV1000, 
79
Olympus, Japan) after 1 day of cell seeding with the density of 5 × 104
cells/mL. Prior to the CLSM observation, the cells were fixed with 4% 
paraformaldehyde solution diluted with PBS for 10 min, and washed with 
PBS 2 times. After that, cells were permeabilized with 0.1% Triton X-100 
(Sigma-Aldrich, USA) diluted with PBS for 5 min, and then washed with PBS 
2 times. Blocking the nonspecific site was performed with 1% bovine serum 
albumin (BSA, Sigma-Aldrich, USA), followed by staining of F-actin and 
nuclei of the cells with phalloidin (Alexa Fluor® 555 phalloidin, Molecular 
Probes, USA) and 4’,5-diamidino-2-phenylindole (DAPI, ProLong Gold®
antifade reagent with DAPI, Invitrogen, USA), respectively. Cell proliferation 
was determined after 1 and 3 days of culturing for evaluating the 
biocompatibility of coating layers on Mg with HUVEC and 3 and 5 days of 
culturing for evaluating in-direct and direct effect of sirolimus with HUVEC 
and VSMC respectively. Cell seeding density was 3 × 104 cells/mL. DNA 
analysis was performed using Cyquant® cell proliferation assay kit (C7026, 
Invitrogen, USA). Before measurements, the cells that adhered to the 
specimens were detached and suspended in a fluorescent dye solution. The 
DNA amount of the detached cells was measured using a multiple plate reader 
(Victor3, PerkinElmer, USA) at 480/535 nm wavelength. The measured 
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florescence values were converted to the DNA amount using a DNA standard 
curve. The standard curve was prepared by measuring the florescence values 
of DNA in buffer solution. In this assay kit, the DNA level was directly 
proportional to the number of living cells. 
3.2.6. Statistical analysis
All data are expressed as mean ± standard deviation (SD). The 
statistical analysis was performed by one-way analysis of variance with 
Bonferroni's post-hoc comparison. A p value inferior to 0.05 was considered 
statistically significant in all cases.
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3.3. Results and discussion
3.3.1. Characterization of selective PEI/PLGA dual 
coated Mg stent
The selective PEI/PLGA dual coated Mg stent was designed to 
expose two different surfaces, luminal surface with PEI coating layer and 
abluminal surface with PEI/PLGA coating layer which PLGA is exposed as 
shown in Figure 3.1. It was achieved by sequential spray coating with PEI full
coating and PLGA asymmetric coating (Figure 3.2.). The surface 
morphologies of bare WE43 stent and selective PEI/PLGA dual coated stent 
was observed. The neodymium (Nd) and yttrium (Y) second phase 
precipitates were found on the surface of bare WE43 stent (Figure 3.3. (a)) 
which were formed during the electro-polishing of the stent [31]. After the 
selective PEI/PLGA dual coating these second phase precipitates were 
covered by the polymer layer. Moreover, after the expansion of the stent 
defects or delamination was not found indicating that the coating layers were
stably adhered on Mg stent (Figure 3.3. (b)). The thickness of the selective 
PEI/PLGA dual coated stent were observed on each luminal and abluminal 
surfaces of the stent as shown in Figure. 3.3. (c) and (d). It was observed that 
the thickness of PEI on the luminal side of the stent was ~ 300 nm. On the 
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contrary, on the abluminal side two layers were observed with ~ 300 nm 
thickness each, indicating the PEI/PLGA dual layer. Selective dual coating
with spray coating method successfully made distinctively asymmetrical 
coating layers on luminal and abluminal side of the stent. Therefore, the
selective dual coating method could be reproduced on actual stent, leading to 
production of the dual-functionalized stent with two different polymer 
surfaces. 
Figure 3.4. shows SEM images of scratch profiles generated from 
progressive load scratch testing on an PLGA or PEI/PLGA dual coated Mg 
substrate. It appears that the scratch profile in PLGA coating is similar to that 
of the PEI/PLGA dual coating at lower scratch loads. This is because the 
surface polymer is both PLGA for mono and dual coating layer. However, as 
the scratch load increases cracks started to appear earlier from the PLGA 
coated Mg. Moreover, delamination of the coating layer started earlier at the 
PLGA coated specimen than dual coated specimen. It indicates that PEI inter 
layer has higher adhesion strength with Mg than that of PLGA and eventually 
results in better corrosion protection of Mg provided by PEI/PLGA dual 
coating than PLGA coating [120]. Furthermore, on the delamination site Mg 
substrate appears rather than smooth polymer layer such as PLGA layer. It 
indicates that PLGA has good interaction with the PEI interlayer. 
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3.3.2. Corrosion behavior of selective PEI/PLGA coated 
Mg stent
Uncoated Mg stent and PLGA or selective PEI/PLGA coated Mg stents 
were immersed in circulating SBF solution. Morphology of the stents were 
observed and the residual volume of the stents were evaluated with m-CT. 
Uncoated Mg stent started to corroded rapidly losing the innate metal color 
compared with coated stents from 1 day as shown in Figure 3.5. Furthermore, 
after 3 days struts of the bare stent started to wash out by the flow of SBF and 
PLGA coated stent also started to corrode rapidly. However, selective 
PEI/PLGA dual coated stent remained the shape until 3 days, showing the 
good corrosion resistance. The dynamic degradation rate of the selective 
PEI/PLGA coated Mg stent was significantly lower than that of the uncoated
and PLGA coated Mg stent (Figure 3.6. and Figure 3.7.). The uncoated Mg
stent corroded rapidly and the struts of the stent were removed by the flow of 
SBF as shown in Figure 3.6. PLGA coated Mg stent seemed to maintain its 
shape until 3 day of the corrosion test. However, corrosion started to occur 
rapidly from 7 days. In contrary, selective PEI/PLGA coated Mg stent 
maintained its shape until 7 days and from 14 days struts on the end of the 
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stent were partially removed due to the local corrosion. Residual volume of 
the stent calculated by m-CT also shows that degradation rate of the selective 
PEI/PLGA coated Mg stent was significantly lower than that of the uncoated 
and PLGA coated Mg stent as shown in Figure 3.7. PLGA coating improved
the corrosion resistance in the early state, however, due to the low adhesion 
strength and stability of PLGA coating corrosion was accelerated after some 
period of time [116, 117]. In contrary, selective PEI/PLGA dual coated stent 
has good corrosion resistance due to the full coated PEI which has good 
adhesion strength and stability results in good corrosion resistant of the 
coating layer [46, 88]. 
3.3.3. Drug release behavior of PEI/PLGA coated Mg 
stent
The effects of the PEI interlayer on sirolimus loaded PLGA were 
shown in Figure 3.8. and Figure 3.9. After immersing sirolimus loaded PLGA 
or PEI/PLGA dual coated Mg substrate in PBS for 1 day, surface morphology 
was observed by SEM (Figure 3.8.). Delamination occurred severely on 
PLGA coated specimen, whereas, PEI/PLGA dual coated specimen showed 
stable morphology of PLGA coating layer. PEI interlayer had a great role of 
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improving corrosion resistance [46, 88] and prohibiting the delamination of 
PLGA from PEI interlayer. Furthermore, the cumulative sirolimus release
profiles were shown in Figure 3.9. The total average amount of loaded 
sirolimus was ~ 0.5 mg/mm2. PLGA coated Mg showed a burst release of 
sirolimus compared with PEI/PLGA dual coated Mg. After 14 days, PLGA 
coated specimen released 79% of the total amount of sirolimus. On the 
contrary, the amount of sirolimus released from the PEI/PLGA dual coated 
specimen was 62% of the total amount of sirolimus. After 17 days both PLGA 
and PEI/PLGA coated specimens released almost 90% of sirolimus and after 
21 days the release amount saturated. According to these results, it is 
suggested that the introduction of PEI coating at the interface between stent 
surface and PLGA layer could promote an efficient sirolimus release from 
PLGA matrix.
3.3.4. In-vitro biocompatibility test
The cell viability and proliferation tests were conducted using
HUVECs and VSMCs. Firstly, to mimic the luminal surface of the stent, 
HUVECs were seeded on bare, PLGA or PEI coated Mg substrate as shown in 
Figure 3.10 (a). Figure 3.10. (b) shows the initial cell adhesion on bare, PLGA 
or PEI coated Mg substrate. On the bare Mg, cells were hardly observed, in a 
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round shape with minimal spreading. The poor cell attachment on bare Mg 
has been attributed to the rapid pH increase and H2 evolution during corrosion 
[29, 50, 93]. However, the large amount of cells was strongly attached on 
PLGA and PEI coated Mg, with well spread out and flattened shape of 
HUVECs. It is also can be observed by the DNA analysis result as shown in 
Figure 3.11. At 1 day the DNA amount which is proportional to the cell 
amount is higher on both coated Mg. However, after 3 days cell amount 
decreased on PLGA coated specimen, whereas, PEI coated specimen had 
highest DNA amount and even increased than 1 day. This is due to the un-
stability of PLGA coating layer on Mg resulting in the rapid corrosion of Mg. 
PEI coating layer improved the corrosion resistance and showing good 
biocompatibility with HUVEC [46, 88, 118].
Furthermore, to evaluate the in-direct effect of sirolimus loaded in 
PLGA coating layer from abluminal surface to luminal surface of the stent,
HUVECs were seeded on PEI coated Mg surface with PEI/PLGA dual coating 
on the bottom side of the specimen. Biological behaviors were compared 
depending on the existence of sirolimus in PLGA layer as shown in Figure 
3.12 (a). Figure 3.12. (b) shows the initial cell adhesion on PEI coating layer 
depending on the existence of sirolimus in PLGA coating layer which is 
beneath the Mg substrate. Both specimens had large amount of cells adhered 
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on PEI coating layer with well spread out and flattened shape. To check the 
effect for longer period of time, proliferation was also evaluated for 3 and 5 
days. As shown in Figure 3.13., DNA analysis showed high cell viability for 
both specimens despite of the existence of sirolimus at 3 and 5 days. It 
indicates that by the selective PEI/PLGA dual coating on Mg stent, amount of 
released sirolimus from abluminal side will have almost no adverse effect on 
HUVEC adhesion and proliferation on PEI coating layer at luminal side of the 
stent. 
To mimic the abluminal surface of the stent and evaluate the direct 
effect of sirolimus, VSMCs were seeded on PEI/PLGA dual coated Mg 
substrate and biological behaviors were evaluated depending on the existence 
of sirolimus in PLGA coating layer as shown in Figure 3.14 (a). Figure 3.14. 
(b) shows the initial cell adhesion of VSMC after 1day. High viability of well 
spread VSMC was seen on PEI/PLGA dual coated Mg without sirolimus, due 
to good biocompatibility of PLGA and good corrosion resistance of 
PEI/PLGA dual coating. On the contrary, on PEI/PLGA dual coated specimen 
with sirolimus had low viability of cells with an almost round shape with 
minimal spreading. Figure 3.15. shows the proliferation of VSMC. PEI/PLGA 
coated specimen without sirolimus in PLGA layer had high viability of cells 
and with good proliferation, whereas, PEI/PLGA coated specimen with 
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sirolimus had low amount of cells at both 3 and 5 days. The poor cell 
attachment and proliferation of VSMC on PEI/PLGA dual coated Mg has 
been mainly attributed to the effect of sirolimus [112, 114].
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3.4. Conclusions
We have demonstrated a drug loaded selective PEI/PLGA dual coating 
by full PEI coating and subsequent abluminal PLGA coating loaded with 
sirolimus on Mg stent for biodegradable drug eluting Mg stent. The PEI 
which has good adhesion strength and good biocompatibility improved both 
corrosion resistance and biocompatibility with HUVEC. Excellent corrosion 
resistance of PEI worked as good interlayer between Mg substrate and 
sirolimus loaded PLGA coating layer to prohibit the delamination of PLGA 
coating layer by preventing the rapid corrosion of Mg stent. Furthermore, 
good biocompatibility of PEI with HUVEC worked as good coating layer on 
luminal side of the stent showing excellent cell adhesion and proliferation of 
HUVEC. PLGA was a good drug eluting polymer coating layer and loaded 
sirolimus effectively suppressed cell adhesion and proliferation of VSMC and 
almost no adverse effect on HUVEC at the luminal side of the stent. 
Consequently, sirolimus loaded selective PEI/PLGA dual coating on Mg stent 




















PEI NMP 3 90 2 100 30 1
PLGA THF 1.5 20 2 300 100 5
Table 3.1. Parameters of spray coating PEI and PLGA on Mg stent
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Figure 3.1. Scheme of selective PEI/PLGA dual coated Mg stent and the 
purpose of PEI and PLGA coating layer corresponding to luminal and 
abluminal surface, respectively
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Figure 3.2. Selective PEI/PLGA dual coating by spray coating process
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Figure 3.3. Surface morphology of (a) uncoated and (b) selective PEI/PLGA 
dual coated Mg stent, and cross sectional image of selective dual coated Mg 
stent on (c) abluminal and (d) luminal side of the stent 
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Figure 3.4. Coating morphology of (a) PLGA coated and (b) PEI/PLGA dual 
coated Mg after scratch test
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Figure 3.5. Optic images of uncoated, PLGA coated or selective PEI/PLGA 
dual coated Mg stent in silicon tube with circulation of SBF solution after (a) 
1 day and (b) 3 days
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Figure 3.6. 3D structural m-CT image of uncoated, PLGA coated, and 
selective PEI/PLGA dual coated Mg stent during dynamic corrosion test
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Figure 3.7. Residual volume of uncoated, PLGA coated, and selective dual 
coated Mg stent during dynamic corrosion test
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Figure 3.8. Surface morphology of sirolimus loaded (a) PLGA and (b) 
PEI/PLGA dual coating layer on Mg after 1 day immersion in PBS
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Figure 3.9. Sirolimus release profile of drug loaded PLGA and PEI/PLGA 
dual coated Mg in PBS
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Figure 3.10. (a) Scheme of the in-vitro cell test procedure and (b) initial cell 
attachment of HUVEC on uncoated, PLGA or PEI coated Mg after 1 day 
culturing
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Figure 3.11. Proliferation of HUVEC on uncoated, PLGA or PEI coated Mg
(**p < 0.005)
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Figure 3.12. In-direct effect of sirolimus on HUVEC at luminal side of the 
stent; (a) Scheme of the in-vitro cell test procedure and (b) initial cell 
attachment on PEI coated Mg depending on the existence of sirolimus in 
PLGA coating layer at abluminal side of the stent
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Figure 3.13. In-direct effect of sirolimus on HUVEC at luminal side of the 
stent; Proliferation on PEI coated Mg depending on the existence of sirolimus 
in PLGA coating layer at abluminal side of the stent (†p > 0.05)
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Figure 3.14. Direct effect of sirolimus on SMC at abluminal side of the stent; 
(a) Scheme of the in-vitro cell test procedure and (b) initial cell attachment on 
PEI/PLGA dual coated Mg depending on the existence of sirolimus in PLGA 
coating layer 
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Figure 3.15. Direct effect of sirolimus on SMC at abluminal side of the stent; 
Proliferation on PEI/PLGA dual coated Mg depending on the existence of 






In this thesis, we aimed to develop a Mg implant that fulfills the two 
main requirements necessary for the biodegradable medical applications, 
namely a low corrosion rate and a good biocompatibility. Furthermore, 
improving the function of these biodegradable implants by fulfilling these 
main requirements, especially for dental/orthopedic and vascular stent 
applications.
Firstly, from chapter 2 for dental and orthopedic application 
biomimetic porous Mg with dense/porous combined structure was fabricated 
by SPS and space holder process for high strength and pore interconnectivity. 
Biomimetic porous Mg had significantly higher mechanical properties 
compared with porous Mg while maintaining the high interconnectivity of the 
pores. Furthermore, to decrease the corrosion rate HA was coated on the 
porous Mg by aqueous precipitation method. However, due to the brittle 
performance of HA, cracks formed on the coating layer propagating to the Mg 
substrate. Cracks effected critically on rapid corrosion due to the complex 
shape and large surface area of porous Mg. Consequently, additional polymer 
layer was needed to be dual coated on the HA layer to cover the cracks and 
improve the corrosion resistance. PEI was a good candidate for the polymer 
dual coating layer due to the high stability. However, due to the deficiency of 
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bioactivity of PEI, bioactive silica nano-particle was hybridized by sol-gel 
method. By sol-gel method silica nano-particles were dispersed well in the 
PEI matrix compared with simple mixing of the silica nano-particle. This PEI-
Silica hybrid coating on HA layer inhibited the corrosion of porous Mg 
remarkably in the SBF solution. Furthermore, the in-vitro cell test and in-vivo
animal test showed the significant improvement of biological activity of PEI-
Silica hybrid coated biomimetic Mg scaffold.
Lastly, chapter 3 focused on the vascular stent application by 
selective PEI/PLGA dual coating for biodegradable drug eluting stent. 
Selective PEI/PLGA coating was performed by spray coating process. PEI 
was fully coated on Mg stent for good corrosion resistance and 
biocompatibility with HUVEC. Subsequently, anti-proliferative drug loaded 
PLGA was coated on the abluminal side of the stent for selective drug release 
to the blood vessel wall to prohibit the excessive proliferation of smooth 
muscle cell and restenosis. Selective PEI/PLGA coating was successfully 
performed by spray coating and this coating decreased the corrosion rate of 
Mg stent in the dynamic corrosion test mimicking the real blood flow. Due to 
the improvement of corrosion resistance of Mg stent, sirolimus was released 
stably and both cell attachment and proliferation of HUVEC were improved 
remarkably. Furthermore, released sirolimus effectively suppressed the VSMC 
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attachment and proliferation indicating for the prevention of restenosis.
This study suggest that PEI-Silica coated biomimetic Mg and 
selective PEI/PLGA dual coated Mg stent offered a great potential for 
dental/orthopedic and vascular stent applications. Depending on these 
applications, HA/PEI-Silica and selective PEI/PLGA dual coating can 
improve the functions of the implants by enhancing the corrosion resistance 
and biocompatibility. Therefore, the study highlighted the functional coatings 
to actively apply Mg to biodegradable medical applications. 
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초록 (Abstract) 
기능성 표면 코팅을 통한 의료용 생분해성





생분해성 임플란트는 생체 내에서 서서히 분해되어 신체
조직의 회복 후 임플란트를 제거하기 위한 2 차 수술이 필요 없는
이상적인 의료용 임플란트로 주목 받고 있다. 생분해성 소재 중
마그네슘과 그 합금은 우수한 기계적 물성과 생체 적합성으로
생분해성 임플란트 소재로써 많은 연구가 진행되고 있으며 특히
치아, 정형외과용 그리고 혈관 스텐트 분야에서 활용하고자
연구되고 있다. 하지만 이러한 우수한 특성에도 불구하고 생체 환경
내에서의 급격한 부식이 일어나 마그네슘 임플란트는 임상
분야에서의 사용이 제한되고 있다. 따라서 마그네슘 임플란트의
기능성 표면 코팅 통해 부식 속도를 늦추고 나아가 생체 친화성을
증진시켜 궁극적으로 임플란트의 기능을 향상시켜야 한다. 
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첫 번째 연구에서는 치아 및 정형외과용 임플란트로
응용하기 위해 생체 모방형 마그네슘에 폴리에터르이미드-실리카
하이브리드를 코팅하였다. 실제 뼈의 구조와 구성 성분을 모방하여
높은 기공 연결성과 기계적 물성과 함께 우수한 뼈 전도성을 얻을
수 있다. 뼈는 조밀한 구조와 다공성 구조가 공존하여 밀도 대비
기계적 강도가 매우 높다. 더욱이, 하이드록시아파타이트가 주요
구성 성분 중 하나로 이 하이드록시아파타이트는 우수한 골
전도성을 지니고 있다. 방전 플라즈마 소결법과 염화나트륨을 기공
형성제로 사용하여 뼈의 구조를 모방한 마그네슘 스캐폴드를
제조할 수 있으며 이렇게 뼈 구조를 모방함으로서 마그네슘
임플란트는 높은 기공 연결성을 지니면서 높은 기계적 강도와
탄성률을 지닐 수 있다. 나아가 조밀한 구조의 비율을 조절함으로서
마그네슘 임플란트의 기계적 강도와 탄성률을 조절할 수 있다. 
그리고 하이드록시아파타이트의 석출 코팅 공정을 통해
하이드록시아파타이트를 마그네슘 임플란트 표면에 코팅할 수 있다. 
이러한 하이드록시아파타이트 코팅층은 마극네슘 임플란트의 부식
저항성과 골세포와의 생체적합성을 동시에 증진 시킬 수 있다. 
하지만 하이드록시아파타이트의 brittle 한 특성으로 인해 코팅층
표면에 크랙과 같은 결함이 발생할 수 있으며 이러한 결함은
마그네슘 다공체의 복잡 형상과 넓은 표면적에 의해 마그네슘
임플란트의 부식과 생체 적합성에 치명적일 수 있다. 따라서
폴리에터르이미드-실리카 유-무기 하이브리드 층을 골 모방형
마그네슘 스캐폴드에 이중 코팅하였다. 폴리에터르이미드의 높은
부식 저항성과 실리카의 우수한 생체 적합성 및 활성도로 인해
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골모방형 마그네슘의 부식 속도를 현저히 감소시킬 수 있었으며
나아가 골 조직의 생성을 촉진 시킬 수 있었다. 따라서
폴리에테르이미드-실리카 하이브리드가 코팅된 골모방형 마그네슘
임플란트는 치아 및 정형외과용 생분해성 스캐폴드로써 우수한
특성들을 지니고 있음을 확인 할 수 있었다.
두 번째 연구에서는 생분해성 약물 방출 스텐트 분야에
응용하기 위해 폴리에테르이미드/폴리락틱-co-글라이콜레이트
이중층을 마그네슘 스텐트의 표면 위치에 따라 선택적으로
코팅하였다. 마그네슘 스텐트는 혈관이 재생될 때 까지 스캐폴드의
지탱력을 유지하여야 하므로 부식 속도를 낮춰야 하며 더욱이
재협착을 방지하기 위해 항증식성 약물이 마그네슘 스텐트로부터
안정적으로 방출되어야 한다. 이러한 특성들을 만족시키기 위해
마그네슘 스텐트에 스프레이 코팅 공정을 통해
폴리에테르이미드/폴리락틱-co-글라이콜레이트 이중층을 스텐트의
외·내벽에 따라 선택적으로 코팅하였다. 마그네슘 스텐트의 부식을
억제하고 혈관표피세포와의 생체친화성을 향상시키기 위해
폴레에테르이미드가 스텐트 전면에 코팅되었다. 이어서 항증식성
약물인 시롤리무스가 담지된 폴리락틱-co-글라이콜레이트가
스텐트 외벽에 선택적으로 코팅되어 혈관 벽 쪽으로의 약물 방출을
유도하였다. 이러한 선택적 약물 방출은 혈관 근육 세포의 증식을
억제할 수 있으며 나아가 약물 방출에 따른 마그네슘 스텐트
내벽에서의 혈관 표피 세포에 미치는 악영향을 억제할 수 있다. 
따라서 마그네슘 스텐트의 선택적 폴리에테르이미드/폴리락틱-co-
글라이콜레이트 이중 코팅은 생분해성 약물 방출 스텐트 분야로서
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적극 응용될 수 있음을 확인 할 수 있었다. 
결과적으로 이러한 연구들은 응용분야에 따른 기능성 표면
코팅을 함으로서 마그네슘 임플란트의 부식 저항성과 생체
적합성을 증진시켜 궁극적으로 마그네슘 임플란트의 기능을
향상시킬 수 있었다. 분해 거동 평가와 세포 실험을 통해
폴리에테르이미드-실리카 하이브리드 코팅과
폴리에테르이미드/폴리락틱-co-글라이콜레이트 이중층의 선택적
코팅은 마그네슘 임플란트의 부식 저항성과 생체 특성을
효과적으로 증진시켜 치아/정형외과 분야와 혈관 스텐트 분야
임플란트로써 우수한 기능을 제공할 수 있음을 확인 할 수 있었다.
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